On 19 February, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares increased 2.81% and was closed at $19.76. ACAD EPS growth in last 5 year was 4.60%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) year to date (YTD) performance is -44.57%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in ACADIA’s New Drug Application (NDA) for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. The Advisory Committee Meeting is scheduled for March 29, 2016.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) shares increased 1.00% in last trading session and ended the day at $1.01. PPHM Gross Margin is 49.70% and its has a return on assets of -59.70%. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) quarterly performance is -10.62%.
Roth Capital reaffirmed their buy rating on shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) in a report published on Friday, Market Beat Ratings reports. Roth Capital currently has a $3.00 price target on the biopharmaceutical company’s stock.
Caterpillar Inc. (NYSE:CAT) caters to the Industrial Goods space. It has a net profit margin of 4.50% and weekly performance is 6.53%. On the last day of trading company shares ended up at $65.42. Caterpillar Inc. (NYSE:CAT) distance from 50-day simple moving average (SMA50) is 2.44%.
Caterpillar Inc. (NYSE:CAT) has announced new responsibilities for its management team, after it had earlier announced plans to restructure, in its guidance for 2016. The changes announced will be effective from March 1, 2016.
Support.com, Inc. (NASDAQ:SPRT) shares advanced 3.47% in last trading session and ended the day at $0.78. SPRT Gross Margin is 20.80% and its has a return on assets of -24.90%. Support.com, Inc. (NASDAQ:SPRT) quarterly performance is -29.45%.
On 10 February, Support.com, Inc. (NASDAQ:SPRT) announced that Dustin Oxborrow has joined the company in the role of Vice President, Sales. Oxborrow brings to Support.com nearly 20 years of experience in technology with more than 10 of those years in SaaS companies.
Aratana Therapeutics, Inc. (NASDAQ:PETX) caters to the Healthcare space. Its weekly performance is 18.11%. On the last day of trading company shares ended up at $3.13. Aratana Therapeutics, Inc. (NASDAQ:PETX) distance from 50-day simple moving average (SMA50) is -4.31%.
On 18 February, Aratana Therapeutics, Inc. (NASDAQ:PETX) filed an application to the Food and Drug Administration in hopes of receiving its first FDA-approved drug, the company announced Wednesday that it’s heading to Europe for another approval.
Leave a Reply